Background: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. Objective: To elucidate PC PSMA expression and associate this with defective DNA damage repair (DDR). Design, setting, and participants: Membranous PSMA (mPSMA) expression was scored immunohistochemically from metastatic castration-resistant PC (mCRPC) and matching, same-patient, diagnostic biopsies, and correlated with next-generation sequencing (NGS) and clinical outcome data. Outcome measurements and statistical analysis: Expression of mPSMA was quantitated by modified H-score. Patient DNA was tested by NGS. Gene expression and activity scores were determined from mCRPC transcriptomes. Statistical correlations utilised Wilcoxon signed rank tests, survival was estimated by Kaplan-Meier test, and sample heterogeneity was quantified by Shannon's diversity index. Results and limitations: Expression of mPSMA at diagnosis was associated with higher Gleason grade (p = 0.04) and worse overall survival (p = 0.006). Overall, mPSMA expression levels increased at mCRPC (median H-score [interquartile range]: castrationsensitive prostate cancer [CSPC] 17.5 [0.0-60.0] vs mCRPC 55.0 [2.8-117.5]). Surprisingly, 42% (n = 16) of CSPC and 27% (n = 16) of mCRPC tissues sampled had no detectable mPSMA (H-score <10). Marked intratumour heterogeneity of mPSMA expression, with foci containing no detectable PSMA, was observed in all mPSMA expressing CSPC (100%) and 37 (84%) mCRPC biopsies. Heterogeneous intrapatient mPSMA expression between metastases was also observed, with the lowest expression in liver metastases. Tumours with DDR had higher mPSMA expression (p = 0.016; 87.5 [25.0-247.5] vs 20 [0.3-98.8]; difference in medians 60 [5.0-95.0]); validation cohort studies confirmed higher mPSMA expression in patients with deleterious aberrations in BRCA2 (p < 0.001; median H-score: 300 [165-300]; difference in medians 195.0 [100.0-270.0]) and ATM (p = 0.005; 212.5 [136.3-300]; difference in medians 140.0 [55.0-200]) than in molecularly unse-
1.
Introduction Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein with enzymatic function as a folate hydrolase-carboxypeptidase [1] . PSMA is predominantly localised to five sites: the prostate, the kidney, salivary glands, nervous system glia, and the small bowel jejunal brush border. In astrocytes and Schwann cells, PSMA has been shown to modulate signal transduction pathways by hydrolysing the neurotransmitter N-acetyl aspartylglutamate (NAAG). At the jejunal brush border, PSMA assists in folate absorption by removing the C-terminal glutamates from dietary folates. The role of PSMA in the prostate is less clear, although it has been implicated in folate and glutamate cellular uptake, which are key to DNA synthesis and repair, amino acid and polyamine generation, and PI3K-Akt signalling [1] [2] [3] .
Nevertheless, PSMA is widely recognised to be overexpressed in prostate cancer (PC) [4, 5] , emerging as a promising target for theranostics. However, concerns remain regarding this strategy. For example, although multiple positron-emission tomography/computed tomography (PET/CT) studies indicate the superiority of PSMA-PET over choline PET [6] , the reported sensitivity of these diagnostic techniques encompasses a broad range [7] . Similarly, while radiolabelled anti-PSMA therapies such as 177 Lu-PSMA-617 appear well tolerated and result in prostate-specific antigen (PSA) level decreases of !50% in 30-60% of metastatic castration-resistant prostate cancer (mCRPC) patients [8, 9] , nonresponder rates of approximately 30% have been reported [9] [10] [11] , with antitumour activity being higher when PSMA-PET based patient selection is pursued.
One potential explanation for these discrepancies is heterogeneity of PSMA expression [12] . However, the extent of, implications of, and mechanisms underlying this phenomenon remain poorly understood due, in part, to previous studies investigating PSMA expression commonly using antibodies, such as the 7E11 anti-PSMA monoclonal antibody, that recognise the intracellular portion of PSMA [4, 5, 13] . As such, these antibodies are susceptible to overestimating PSMA expression, given that they recognise cytoplasmic PSMA, which is not clinically actionable, as evidenced by early clinical trials of radioimmunoconjugates using these antibodies that showed poor antitumour activity [14, 15] . Subsequently, new antibodies that recognise the extracellular portion of PSMA have been developed [16] , allowing more accurate assessment of PSMA expression. However, despite this, more recent publications have been limited by a lack of differentiation between cytoplasmic PSMA expression and more clinically relevant membranous PSMA (mPSMA) [17, 18] . We therefore elected to evaluate, by immunohistochemistry (IHC), the variability of mPSMA protein expression in mCRPC biopsies and, when available, the matching, same-patient, diagnostic, castration-sensitive prostate cancer (CSPC) biopsies, to determine the extent of PSMA heterogeneity and how this may impact the clinical utility of PSMA-theranostic strategies. Furthermore, given that intratumour heterogeneity can be significantly increased by genomic instability [19] , we have also pursued next-generation sequencing (NGS) studies to determine whether deleterious DNA damage repair (DDR) aberrations, which are a well-described contributor to genomic instability [20, 21] , are associated with PSMA protein expression and whether DDR biomarkers can have utility for guiding PSMA-directed therapies.
2.
Patients and methods [27] . All analyses were conducted using Stata v13.1; graphs were generated using GraphPad Prism v7.
Patients and tissue samples

Gene expression and activity scores
Results
Antibody validation
To emulate PSMA-targeted diagnostics and theranostics currently under clinical evaluation, anti-PSMA subclone 3E6, which targets an extracellular epitope of PSMA, was chosen over the 7E11 subclone, which recognises the intracellular portion of PSMA. Antibody specificity was validated by Western blot demonstrating a reduction in detectable PSMA protein expression following treatment with PSMA-specific siRNA compared with nontargeting control siRNA ( Fig. 1B and Supplementary Fig. 2 ).
Expression of mPSMA protein at diagnosis of PC is heterogeneous and associated with a worse overall survival
Expression levels of mPSMA protein were evaluated in 38 CSPC PC biopsies obtained at diagnosis (median H-score [interquartile range]: 17.5 [0.0-60.0]). Interestingly, 16 (42%; 95% confidence interval [CI; 28-58%]) patient samples had no detectable expression of mPSMA (H-score <10). Furthermore, amongst the remaining biopsies that expressed PSMA, there was not only apparent interpatient heterogeneity, but also marked intrapatient heterogeneity in expression, with all evaluated tissue samples exhibiting areas without detectable PSMA (Fig. 1C ). To quantify this intratumour heterogeneity, each tumour biopsy was assigned an SDI score; this revealed that not only did all biopsies with detectable mPSMA exhibit heterogeneous expression, but also that the degree of intrapatient heterogeneity increased in parallel with mPSMA H-score.
To determine the clinical significance of mPSMA at PC diagnosis, the association of mPSMA expression with clinical characteristics and OS was determined. Higher levels of mPSMA expression were associated with a higher Gleason grade (p = 0.04; Supplementary Table 2 ) and a worse overall survival (hazard ratio [95% CI]: H-score <17.5 = 1.00 vs H-score !17.5 = 2.97 [1.38-6.43]; p = 0.006) when dichotomised by the median H-score ( Fig. 1H ). Taken together, these data indicate that in addition to a large proportion of patients exhibiting no detectable PSMA expression in their tumour biopsies at diagnosis of PC, when mPSMA is present, its expression is inherently heterogeneous. Furthermore, although the patient cohort presented here is relatively limited in size, making inferences on the impact of PSMA expression on survival more challenging, our results suggest that mPSMA expression at PC diagnosis is associated with a poor prognosis and a more aggressive histological phenotype, meriting further evaluation in larger prospective datasets. Expression of mPSMA protein is upregulated in mCRPC, but demonstrates marked intra-and interpatient heterogeneity
Median mCRPC mPSMA H-score was 55.0 ([2.8-117.5]; n = 60). Importantly, 16 (27% [17-39%]) mCRPC biopsies had no detectable expression of mPSMA, with only one patient (patient 11) having evidence of neuroendocrine differentiation. Interestingly, a comparison with matched, samepatient CSPC tissue samples revealed that half of these samples with no mPSMA protein expression were also negative for mPSMA expression at PC diagnosis. In keeping with our findings in CSPC biopsies, 37 of the 44 (84% [71-92%]) mCRPC biopsies expressing mPSMA demonstrated marked heterogeneity in expression ( Fig. 2A) , with SDI scores similarly increasing in line with the H-score. While the degree of heterogeneity in mPSMA expression varied between patient samples, common patterns of mPSMA expression were identified. These included the following:
(1) PSMA-positive and PSMA-negative cells interspersed within a single area of prostate adenocarcinoma (Fig. 2C) ;
(2) clusters of adenocarcinoma cells with strong PSMA expression intertwined within regions of PSMA-null tumour cells (Fig. 2D) ; and (3) discrete nodular PSMA expression, with regions of PSMA-negative tumour cells segregated away from regions of PSMA expressing cells, a number of which were >2 mm apart, which is the maximal tissue penetrance of the beta particle emitter 177 Lu (Fig. 2F ). Furthermore, heterogeneous mPSMA expression between metastases from the same patient was also observed (Fig. 2G ). To determine whether mPSMA expression levels were dependent on the type of tissue biopsied, mPSMA expression was correlated with mCRPC biopsy site. No difference was observed between samples obtained from bone (n = 25) and lymphoid tissue (n = 22); however, interestingly, a significant reduction in mPSMA expression was observed in liver metastases (n = 8), with none of these biopsies demonstrating overt neuroendocrine differentiation. Taken together, these data indicate that while mPSMA increases in mCRPC, a significant proportion of patients exhibit no detectable PSMA. When present, however, mPSMA expression in mCRPC exhibits marked intra-and interpatient heterogeneity, resulting in clinically significant distances between areas of PSMA-expressing and PSMAnull cells, potentially impacting the clinical utility of PSMA theranostics. Furthermore, while absence of mPSMA expression at diagnosis was associated with a lack of mPSMA mCRPC expression, there was poor concordance between mPSMA expression at diagnosis of PC and at castration-resistant disease.
Expression of mPSMA protein in mCRPC is associated with deleterious DNA repair aberrations
In light of the observed marked heterogeneity of mPSMA expression, and given that intratumour heterogeneity can be significantly increased by genomic instability [19] , targeted NGS data were analysed to identify potential associations between mPSMA expression and deleterious DDR aberrations (Fig. 3A) . Interestingly, mCRPC patients with deleterious DDR aberrations were found to have significantly higher (p = 0.016) mPSMA expression than those without these aberrations (DDR 87. Fig. 3B ). Furthermore, when comparing the change in mPSMA protein expression between matched, same-patient CSPC and mCRPC tissue samples, we observed that while mPSMA expression increased significantly in mCRPC patients with detectable DDR aberrations (p = 0.02), this was not the case for patients without detectable DDR gene mutations (p = 0.19) (Coef = 35; 95% CI: 2-68; p = 0.04; Fig. 3C ). Interestingly, in keeping with these findings, although not statistically significant, amongst the 37 patients within our patient cohort who received treatment with a PARP inhibitor, nine of the 11 (82%) patients who responded to therapy had a mPSMA H-score above the median (55.0 [2.8-117.5]). To validate the association between mPSMA expression and deleterious DDR aberrations, mCRPC mPSMA expression levels were evaluated in an independent PC cohort with known DDR aberrations. Tumours with deleterious DDR aberrations were found to have significantly higher mPSMA expression levels than unselected mCRPC biopsies (BRCA2 300 [165- , p = 0.03; Fig. 3D ). Taken together, these data suggest that deleterious DDR aberrations are associated with significantly higher mPSMA expression levels in mCRPC.
3.5.
Metastatic CRPC transcriptome analyses: PSMA, doublestrand break repair, BRCA2, and epithelial-mesenchymal transition
To further explore the association between PSMA expression and DNA repair, analysis of RNA-sequencing data obtained from 163 mCRPC transcriptomes was performed (SU2C/PCF validation cohort). This demonstrated an inverse correlation between PSMA mRNA expression, and both BRCA2 mRNA expression (p < 0.001; Fig. 4A ) and double-strand break repair (p < 0.001; Fig. 4C ), which, taken together, suggest that high PSMA expression in mCRPC is associated with BRCA2 loss and a reduction in homology-dependent DNA repair. Furthermore, since RB1 can be codeleted with BRCA2, with emerging endocrine resistance and luminal to basal transition with associated hyperexpression of SOX2, we correlated SOX2 expression with PSMA expression [28, 29] . PSMA expression correlated negatively and robustly with SOX2 (p < 0.001; Fig. 4D ), SNAI1 (p < 0.001; Fig. 4E ), SNAI2 (p = 0.039; Fig. 4F ), NCAM1 (p < 0.001; Fig. 4G ), and EON2 (p < 0.001; Fig. 4H ) expression levels, suggesting downregulation of PSMA expression with luminal to basal transition and the neuroendocrine-like phenotype.
Discussion
The protein PSMA, which is arguably critical to folate and glutamate PC cell uptake necessary for maintaining genomic stability, has become a key target for PC theranostics [8] [9] [10] [11] . Early-phase trials of PSMA-targeting theranostics, including immunoconjugates, radioimmunoconjugates car- rying alpha-and beta-emitting particles, and bispecific antibodies targeting CD3 and PSMA, have reported antitumour activity against mCRPC. These trials have often recruited patients with positive PSMA-ligand uptake on PET [10, 11] ; however, this patient selection is not always being pursued so as to minimise cost. De novo and acquired resistance to these agents has also been reported, and is likely to be at least in part related to the absence or loss of PSMA expression, although the mechanisms for these have not been fully elucidated to date. A better understanding of inter-and intratumour heterogeneity in PSMA expression is now key to successful development of these agents. We now present the first robust evidence that PC PSMA expression is strongly associated with DNA repair defective tumours, perhaps explaining why therapeutics that generate doublestrand DNA breaks, such as radioimmunoconjugates, have had antitumour activity against PC. We propose that future trials with these agents should consider targeting DDR PC. These data are supported by a recent case report of an exceptional response to 177 Lu in a patient harbouring BRCA2 loss [30] . While our analyses presented here focus on mPSMA, given that we believe that this represents a more clinically relevant measure of PSMA expression in PC, we acknowledge that differentiation between membranous and cytoplasmic PSMA expression, particularly in cases where [ ( F i g . _ 4 ) T D $ F I G ] Fig. 4 -PSMA mRNA expression is inversely correlated with BRCA2 mRNA expression and double-strand break repair. Analysis of RNA-sequencing data obtained from 163 mCRPC transcriptomes demonstrating an inverse correlation between PSMA mRNA expression, and (A) BRCA2 mRNA expression (p < 0.001) and (B) ATM mRNA expression (p = 0.059), associating PSMA expression with BRCA2 loss. (C) An inverse correlation was observed between PSMA mRNA expression and an mRNA signature of double-strand break repair activity (p < 0.001) calculated through cumulative measurement of 19 genes involved in homologous recombination DNA repair, as determined from the Molecular Signatures Database (M11429), indicating that as PSMA mRNA expression increases, DDR activity decreases. (D) PSMA expression was also found to be inversely correlated with SOX2 mRNA expression (p < 0.001), as well as with (E) SNAI1 (p < 0.001), (F) SNAI2 (p = 0.039), (G) NCAM1 (p < 0.001), and (H) ENO2 (p < 0.001) expression levels, suggesting a downregulation of PSMA expression with luminal to basal transition and the neuroendocrine-like phenotype. DDR = defective DNA repair; FPKM = Fragments Per Kilobase of transcript per Million mapped reads; mCRPC = metastatic castration-resistant prostate cancer; PSMA = prostatespecific membrane antigen. cytoplasmic PSMA expression is high, may be a limitation of our work. Despite this, our data herein indicate that the inherent intratumour heterogeneity of PSMA expression in PC represents a significant potential contributor to resistance to these therapies. Furthermore, while our conclusions are limited by the retrospective nature of our study and the relatively small size of our patient cohorts, we envision that trials that do not mandate evidence of PSMA expression prior to enrolment will inevitably observe lower rates of response. Moreover, our data indicating that liver metastases in mCRPC have very low PSMA expression also raise concern that patients suffering from these may not benefit from these therapies, with these tumours perhaps being more likely to have an emerging basal phenotype [31] [32] [33] . Further studies are now needed to determine whether this will be a commoner site of resistance to PSMA-targeting therapies.
The association between PSMA and deleterious DDR aberrations also raises many interesting questions for future study. Importantly, we do not propose that deleterious DDR aberrations alone cause increased expression of PSMA. Rather, we hypothesise that the biological consequences for tumour cells of having deleterious aberrations in DDR genes potentially promote the overexpression of PSMA. Deleterious DDR aberrations are associated with replication stress, placing increased demand for metabolic precursors such as folate and glutamate, which are crucial to DNA synthesis and repair. As such, given the enzymatic capability of PSMA to yield glutamate and folate monoglutamate from polyglutamated folates [2] , and its reported role as a folate transporter [1] , one possible explanation to account for this association is that PSMA overexpression in cells with deleterious DDR aberrations represents an adaptive cellular response. In this setting, PSMA overexpression may be being driven by the increased requirement of these cells for cellular metabolites such as folate and glutamate. Alternatively, PSMA has also been reported to promote PI3K-Akt signalling [3, 34] . This has been demonstrated to suppress DNA repair by homologous recombination, which is defective in cells with deleterious DDR aberrations such as BRCA2 loss, and also to enhance nonhomologous end joining [35] . This again hints towards PSMA serving as a survival mechanism for PC cells with DDR. Most likely, however, the mechanisms underlying the expression of PSMA are multifactorial, involving a complex interaction between numerous cellular processes. In spite of these uncertainties, it is clear that a deeper understanding of the biology of PSMA in PC is now needed, firstly, to account for this association, but also to elucidate pharmacological strategies that can manipulate PSMA expression, for example, perhaps through generating PC genomic instability or replication stress. Such strategies may inform on the development of optimal drug combinations for PSMA-targeting therapeutics.
Conclusions
Expression of mPSMA is upregulated in many but not all PCs, and exhibits marked intra-and interpatient heterogeneity. DDR gene aberrations are associated with significantly higher mPSMA expression levels and merit further evaluation as predictive biomarkers of response for PSMA-targeted therapies in larger, prospective clinical trials.
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